A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Sponsor: AbbVie
Terminated
Strategic considerations
Other terminated trials from AbbVie
Other Small Cell Lung Cancer trials with similar outcome
Listed as NCT02819999, this PHASE1 trial focuses on Small Cell Lung Cancer and remains terminated or withdrawn. Sponsored by AbbVie, it has been updated 13 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 8 earlier versions
-
Jul 2019 — Apr 2020 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Jun 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE1
-
Mar 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE1
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .